Regeneron Pharmaceuticals ((REGN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: Regeneron Pharmaceuticals is conducting a Phase 2 trial titled A Phase 2 Peri-Operative Trial of Fianlimab and Cemiplimab in Combination With Chemotherapy Versus Cemiplimab in Combination With Chemotherapy in Patients With Resectable Early Stage (Stage II to IIIB [N2]) NSCLC. The study aims to evaluate the safety and efficacy of combining fianlimab, cemiplimab, and chemotherapy compared to cemiplimab and chemotherapy alone in treating resectable non-small cell lung cancer (NSCLC). This research is significant as it explores potential improvements in peri-operative therapy for NSCLC patients.
Intervention/Treatment: The study tests the combination of fianlimab (REGN3767), cemiplimab, and platinum-doublet chemotherapy. Fianlimab and cemiplimab are administered intravenously every three weeks, aiming to enhance treatment efficacy and patient outcomes in NSCLC.
Study Design: This interventional study is randomized with a parallel assignment model. It employs quadruple masking, meaning participants, care providers, investigators, and outcomes assessors are blinded to the treatment allocations. The primary purpose is treatment-focused, aiming to determine the best therapeutic approach for NSCLC.
Study Timeline: The study began on November 29, 2023, and is currently recruiting participants. The latest update was submitted on August 22, 2025. These dates are crucial for tracking the study’s progress and anticipating when results might influence clinical practices and market dynamics.
Market Implications: This study could significantly impact Regeneron’s market position, potentially boosting its stock if the combination therapy proves more effective. Positive results might enhance investor confidence and position Regeneron favorably against competitors in the oncology sector, particularly in the NSCLC treatment landscape.
The study is ongoing, with further details available on the ClinicalTrials portal.